/
CSTL
$30.55-$0.88 (-2.80%)prev close
Held by
0
portfolios on TandT
Bookmarked by
0
users
Avg position size
—
of holders' portfolios
13F filers
1
institution
Market cap
$960.2M
31M shares
52-week range
$17.72 – $44.28
48% from low
Sector
SERVICES-MEDICAL LABORATORIES
Exchange
NASDAQ
CS
Change$-30.47
Castle Biosciences, Inc. Common Stock
Castle Biosciences Inc is a molecular diagnostics company. The group provides test solutions for the diagnosis and treatment of dermatologic cancers, Barrett's esophagus (BE), and uveal melanoma. The product portfolio of the company includes DecisionDx-Melanoma, a risk stratification gene expression profile (GEP) test; DecisionDx-SCC, a risk stratification test for cutaneous squamous cell carcinoma; MyPath Melanoma, a diagnostic GEP test for use in patients with difficult-to-diagnose melanocytic lesions; and TissueCypher, a test to predict future development of progression of high-grade dysplasia and/or esophageal cancer. The company derives revenues through the delivery of test reports for its molecular diagnostic tests.
www.castlebiosciences.com- Employees
- 1,002
- IPO / List date
- Jul 25, 2019
- HQ
- FRIENDSWOOD, TX
Held by traders on TradeandTell
No one on the platform currently holds CSTL.
Super investors & insiders
Institutions holding (13F)
| Institution | Shares | Reported |
|---|---|---|
| Renaissance Technologiesas of 2026-03-31 | 532,800 | $13.1M |
Insider activity (SEC Form 4)
Recent trades on TradeandTell
No one on the platform has traded CSTL yet.
